Nagle et al. [29] have provided insights into this aspect, reporting that among 31 patients with R/R DLBCL treated with anti-CD19 CAR T-cell therapy, the 1-year OS rate in patients with PTH is notably lower compared to those without PTH (36% vs. 81%, P < 0.05). This evidence concerns the gene PTH and diffuse large B-cell lymphoma.